Citations

Clear

18 citation(s) found for "Nathan, Mark".

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer
Reddy, Shantan, Bahary, Nathan , Uronis, Hope E. , Sigal, Darren , Cohn, Allen Lee, Schelman, William R., Stephenson, Joe , Chiorean, E. Gabriela , Rosen, Peter J., Ulrich, Brian, Dragovich, Tomislav , Prete, Salvatore A. Del , Rarick, Mark U., Eng, Clarence, Kroll, Stew, Ryan, David P. , Reddy, Shantan G, Cohn, Allen L, Del Prete, Salvatore A, Rarick, Mark, Borad, Mitesh J.

Mayo Clinic

Journal of Clinical Oncology | December 16, 2014 | Volume: 33 | Issue: 13 | Pages: 1475-1481

10.1200/jco.2014.55.7504 | PMID 25512461 Get It

Purpose TH-302 is an investigational hypoxia-activated prodrug that releases the DNA alkylator bromo-isophosphoramide mustard in hypoxic settings. This phase II study (NCT01144455) evaluated gemcitabine plus TH-302 in patients with previously untreated, locally advanced or metastatic pancreatic cancer. Patients and Methods Patients were randomly assigned 1:1:1 to gemcitabine (1,000 mg/m2), gemcitabine plus TH-302 240 mg/m2 (G+T240), or gemcitabine plus TH-302 340 mg/m2 (G+T340). Randomized crossover after progression on gemcitabine was allowed. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), tumor response, CA 19-9 response, and safety. Results Two hundred fourteen patients (77% with metastatic disease) were enrolled between June 2010 and July 2011. PFS was significantly longer with gemcitabine plus TH-302 (pooled combination arms) compared with gemcitabine alone (median PFS, 5.6 v 3.6 months, respectively; hazard ratio, 0.61; 95% CI, 0.43 to 0.87; P = .005; median PFS for metastatic disease, 5.1 v 3.4 months, respectively). Median PFS times for G+T240 and G+T340 were 5.6 and 6.0 months, respectively. Tumor response was 12%, 17%, and 26% in the gemcitabine, G+T240, and G+T340 arms, respectively (G+T340 v gemcitabine, P = .04). CA 19-9 decrease was greater with G+T340 versus gemcitabine (−5,398 v −549 U/mL, respectively; P = .008). Median OS times for gemcitabine, G+T240, and G+T340 were 6.9, 8.7, and 9.2 months, respectively (P = not significant). The most common adverse events (AEs) were fatigue, nausea, and peripheral edema (frequencies similar across arms). Skin and mucosal toxicities (2% grade 3) and myelosuppression (55% grade 3 or 4) were the most common TH-302–related AEs but were not associated with treatment discontinuation. Conclusion PFS, tumor response, and CA 19-9 response were significantly improved with G+TH-302. G+T340 is being investigated further in the phase III MAESTRO study (NCT01746979).
Update on positron emission tomography for imaging of prostate cancer
Kitajima, Kazuhiro , Nathan, Mark A., Sugimura, Kazuro , Murphy, Robert C.

Mayo Clinic

International Journal of Urology | September 2, 2013 | Volume: 21 | Issue: 1 | Pages: 12-23

10.1111/iju.12250 | PMID 23991644 Get It

AbstractProstate cancer is the most common non‐cutaneous malignancy among men in the Western world, and continues to be a major health problem. Imaging has recently become more important in the clinical management of prostate cancer patients, including diagnosis, staging, choice of optimal treatment strategy, treatment follow up and restaging. Positron emission tomography, a functional and molecular imaging technique, has opened a new field in clinical oncological imaging. The most common positron emission tomography radiotracer, 18F‐fluorodeoxyglucose, has been limited in imaging of prostate cancer. Recently, however, other positron emission tomography tracers, such as 11C‐acetate and 11C‐ or 18F‐choline, have shown promising results. In the present review article, we overview the potential and current use of positron emission tomography or positron emission tomography/computed tomography imaging employing the four most commonly used positron emission tomography radiotracers, 18F‐fluorodeoxyglucose, 11C‐acetate and 11C‐ or 18F‐choline, for imaging evaluation of prostate cancer.
Lung Cancer Screening Experience: A Retrospective Review of PET in 22 Non-Small Cell Lung Carcinomas Detected on Screening Chest CT in a High-Risk Population
Lindell, Rebecca M. , Hartman, Thomas E. , Swensen, Stephen J., Jett, James R., Midthun, David E. , Nathan, Mark A., Lowe, Val J.

Mayo Clinic

American Journal of Roentgenology | February 28, 2013 | Volume: 185 | Issue: 1 | Pages: 126-131

10.2214/ajr.185.1.01850126 | PMID 15972412 Get It

Time Interval Between Abnormalities Seen on CT and the Clinical Diagnosis of Pancreatic Cancer: Retrospective Review of CT Scans Obtained Before Diagnosis
Gangi, Sumana, Nathan, Mark A., Christensen, Jared A. , Harmsen, William S. , Crownhart, Brian S., Chari, Suresh T. , Fletcher, Joel G. , Chari, Suresh T

Mayo Clinic

American Journal of Roentgenology | February 28, 2013 | Volume: 182 | Issue: 4 | Pages: 897-903

10.2214/ajr.182.4.1820897 | PMID 15039161 Get It

Abstract LB-121: Randomized phase II study of the efficacy and safety of gemcitabine + TH-302 (G+T) vs gemcitabine (G) alone in previously untreated patients with advanced pancreatic cancer
Reddy, Shantan, Uronis, Hope E. , Sigal, Darren , Cohn, Allen Lee, Schelman, William R., Chiorean, E. Gabriela , Rosen, Peter J., Ulrich, Brian, Prete, S. Del , Rarick, Mark U., Kroll, S., Ryan, David P. , Borad, Mitesh J. , Stephenson, John R. , Dragovich, Tomislav , Eng, Charis

Mayo Clinic

Cancer Research | August 13, 2012 | Volume: 72 | Issue: 8_Supplement | Pages: LB-121-LB-121

10.1158/1538-7445.am2012-lb-121 Get It

Abstract A hypoxic microenvironment is believed to be a characteristic of solid tumors including pancreatic adenocarcinoma (PAC) and is associated with resistance to chemotherapy. The hypoxia-activated prodrug, TH-302, is designed to specifically target the hypoxic microenvironment. Combining G with TH-302 may enable the targeting of both the normoxic and hypoxic regions of PAC. TH-302 was investigated with full-dose G as part of a Phase 1/2 study with a 21% response, median PFS and OS of 5.9 and 8.5 months, respectively, and one-year survival of >40%. Based upon these data, a randomized Phase 2B study (NCT01144455) was conducted to assess the benefit of G+T to standard dose G for first-line therapy of PAC. An open-label multi-center study of two dose levels of TH-302 (240 mg/m2 or 340 mg/m2) in combination with G versus G alone (randomized 1:1:1) was initiated in June 2010. G (1000 mg/m2) and T were administered IV over 30-60 minutes on Days 1, 8 and 15 of a 28-day cycle. Patients on the G arm could crossover after progression and be randomized to a G+T arm. The primary efficacy endpoint is a comparison of progression-free survival (PFS) between the combination arms and G alone (80% power to detect 50% improvement in PFS with one-sided alpha of 10%). 214 pts (69 G: 71 G+T240: 74 G+T340) with advanced PAC including 77% distant metastases, 62% involving liver and 11% with prior adjuvant tx; median age: 65 (range 29-86); 126 M/88 F; 79/128 ECOG 0/1. Median cycles received: G - 4, G+T240 - 5, G+T340 - 6. Median PFS was 3.6 mo in G vs 5.6 mo in G+T arms with HR of 0.61 (95% CI: 0.43 - 0.87) and logrank p-value of 0.005. Median PFS in G + T340 was 6.0 mo. RECIST best response was 12% in G, 17% in G+T 240 and 27% in G+T340. 153 (71%) patients had elevated CA19-9 and follow-up. CA19-9 decreases were significantly greater in the G+T groups and greatest in the G+T340 arm which had 37 of 53 (70%) pts with a greater than 50% CA19-9 decrease. One death (suicide) was considered possibly related to study drug. Adverse events leading to discontinuation were: 16% G, 15% G+T240 and 11% G+T340. Serious adverse events were balanced across the treatment arms. The most common non-laboratory events, fatigue (49%), nausea (43%), constipation (34%) and peripheral edema (38%), were similar across groups. Rash (14% G, 39% G+T240 and 45% G+T340) and stomatitis (6% G, 17% G+T240 and 36% G+T340) were significantly greater with G+T combination but no Grd 4 (4 pts with Grade 3). Grd 3/4 thrombocytopenia (11% G, 39% G+T240 and 59% G+T340) and Grd 3/4 neutropenia (28% G, 56% G+T240 and 59% G+T340) were higher with G+T. G+T combination with full dose G improved the efficacy of G with significantly longer PFS, higher response rate and greater CA19-9 declines. The G+T combination was well tolerated. Skin and mucosal toxicity and myelosuppression were the most common related adverse events with no increase in treatment discontinuation. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-121. doi:1538-7445.AM2012-LB-121
18 F-FDG PET in the Management of Patients with Anaplastic Thyroid Carcinoma
Bogsrud, Trond Velde , Karantanis, Dimitrios, Nathan, Mark A., Mullan, Brian P., Wiseman, Gregory A., Kasperbauer, Jan L. , Reading, Carl C., Lowe, Val J. , Hay, Ian

Mayo Clinic

Thyroid® | July 17, 2008 | Volume: 18 | Issue: 7 | Pages: 713-719

10.1089/thy.2007.0350 | PMID 18630999 Get It

Background: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive solid tumors in humans. The use of positron emission tomography (PET) with 18 F-fluorodeoxyglucose ( 18 F-FDG) in ATC has not been studied, and only a few case reports have been published. The objective of this study was to investigate the potential contribution of 18 F-FDG PET to the clinical management of patients with ATC. Methods: All patients with ATC studied with 18 F-FDG PET from August 2001 through March 2007 were included. The PET results were correlated with computed tomography, ultrasound, magnetic resonance imaging, bone scan, histology, and clinical follow-up. The FDG uptake was semiquantified as maximum standard uptake value. Any change in the treatment plan as a direct result of the PET findings as documented in the clinical notes was recorded. Results: Sixteen patients were included. True-positive PET findings were seen for all primary tumors, in all nine patients with lymph node metastases, in five out of eight patients with lung metastases, and in two patients with distant metastases other than lung metastases. In 8 of the 16 patients, the medical records reported a direct impact of the PET findings on the clinical management. Conclusions: ATC demonstrates intense uptake on 18 F-FDG PET images. In 8 of the 16 patients (50%), the medical records reported a direct impact of the PET findings on the management of the patient. PET may improve disease detection and have an impact on the management of patients with ATC relative to other imaging modalities.
Characterization of the Solitary Pulmonary Nodule: 18F-FDG PET Versus Nodule-Enhancement CT
Christensen, Jared A. , Nathan, Mark A., Mullan, Brian P., Hartman, Thomas E. , Swensen, Stephen J., Lowe, Val J.

Mayo Clinic

American Journal of Roentgenology | October 20, 2006 | Volume: 187 | Issue: 5 | Pages: 1361-1367

10.2214/ajr.05.1166 | PMID 17056930 Get It

Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo
Noble, Wendy , Planel, Emmanuel , Zehr, Cindy, Olm, Vicki, Meyerson, Jordana L. , Gaynor, Kate, LaFrancois, John J., Feinstein, Boris, Burns, Mark P. , Krishnamurthy, Pavan, Bhat, Ratan V. , Lewis, Jada , Dickson, Dennis W. , Duff, Karen , Suleman, Farhana E. , Wang, Lili , Yi, Wen , Dickson, Dennis W

Mayo Clinic

Proceedings of the National Academy of Sciences | May 2, 2005 | Volume: 102 | Issue: 19 | Pages: 6990-6995

10.1073/pnas.0500466102 | PMID 15867159 Get It

Neurofibrillary tangles composed of hyperphosphorylated, aggregated tau are a common pathological feature of tauopathies, including Alzheimer's disease. Abnormal phosphorylation of tau by kinases or phosphatases has been proposed as a pathogenic mechanism in tangle formation. To investigate whether kinase inhibition can reduce tauopathy and the degeneration associated with it in vivo , transgenic mice overexpressing mutant human tau were treated with the glycogen synthase kinase-3 (GSK-3) inhibitor lithium chloride. Treatment resulted in significant inhibition of GSK-3 activity. Lithium administration also resulted in significantly lower levels of phosphorylation at several epitopes of tau known to be hyperphosphorylated in Alzheimer's disease and significantly reduced levels of aggregated, insoluble tau. Administration of a second GSK-3 inhibitor also correlated with reduced insoluble tau levels, supporting the idea that lithium exerts its effect through GSK-3 inhibition. Levels of aggregated tau correlated strongly with degree of axonal degeneration, and lithium-chloride-treated mice showed less degeneration if administration was started during early stages of tangle development. These results support the idea that kinases are involved in tauopathy progression and that kinase inhibitors may be effective therapeutically.